Latest Research News | |||||
|
| ||
Families of SMA announce novel drug program for SMA. | ||
| ||
Repligen Corporation announces successful Phase I clinical trial of drug with potential to treat SMA. | ||
| ||
Biomarker assay panel launched by The SMA Foundation and Myriad RBM. | ||
| ||
NeuroNEXT announces new SMA biomarker study. | ||
| ||
The BBC has published a short article on work from Thomas Gillingwater's laboratory (previously reported on by the Jennifer Trust). | ||
| ||
Motor Neurones and Diseases of Motor Neurones - international conference to be held in Edinburgh, 10-12th July 2012. | ||
| ||
New research in SMA mice provides evidence that increasing SMN levels during early stages of symptom onset may still help to lessen disease pathology and halt the progression of SMA. | ||
| ||
Biogen Idec enters a global agreement with ISIS Pharmaceuticals to develop and commercialise ISIS-SMNRx, which has shown promise as a potential treatment for SMA. | ||
| ||
New research from the Pellizzoni group at Columbia University, NY, USA identifies a plausible explanation for the motor neuron susceptibility seen in SMA. | ||
| ||
ISIS Pharmaceuticals initiate a Phase I clinical trial of their antisense oligonucleotide drug ISIS-SMNRx. | ||
| |||||
